

Appendix 1, as supplied by the authors. Appendix to: Lexchin J. Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study. CMAJ Open 2022. doi:10.9778/cmajo.20220063. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Supplementary file 1: data extracted from databases

Generic name	Date New Drug Submission filed	Date of Notice of Compliance (market approval)	Date of marketing	Type of decision	Date of CADTH decision	CADTH submission dates	Additional therapeutic value (best rating from HDAP)			Date of pCPA / pCPA decision	pCPA decision
							Major	Moderate	Little to none		
Brentuximab	2012-04-11	2013-02-01	2013-02-19	Reimburse with clinical criteria and/or conditions	2013-08-29	2013-03-14			1	2014-01-31	Positive
Riociguat	2013-02-25	2013-09-19	2013-09-25	List with criteria/condition	2014-07-17	2013-09-30			1	2015-01-23	Positive
Lixisenatide	2016-04-26	2017-05-25	2017-09-12	Reimburse with clinical criteria and/or conditions	2017-11-23	2017-05-29			1	2019-11-21	Positive
Erenumab	2017-08-18	2018-08-01	2018-12-04	Reimburse with clinical criteria and/or conditions	2020-07-22	2019-05-02			1	2021-12-13	Negative
Fremanezumab	2019-05-01	2020-04-09	2020-08-04	Reimburse with clinical criteria and/or conditions	2021-03-24	2020-06-03			1	2021-12-03	Positive
Netupitant, palonestron	2016-10-13	2017-09-28	2017-11-20	Reimburse with clinical criteria and/or conditions	2018-06-20	2017-12-08				2019-04-24	Positive
Alectinib	2015-11-12	2016-09-29	2016-10-14	Reimburse with clinical criteria and/or conditions	2017-05-04	2016-10-03			1	2018-12-11	Positive
Palonosetron	2011-03-31	2012-03-14	2012-06-19	Do not list	2013-04-24	2012-10-05		1		2013-08-21	Negotiations not pursued
Brigatinib	2017-10-24	2018-07-26	2018-08-31	Do not reimburse	2019-08-01	2018-12-05				2021-12-16	Positive
Umeclidinium and vilanterol	2013-01-10	2013-12-23	2014-03-14	List with criteria/condition	2015-01-15	2014-02-26			1	2015-05-01	Positive
Eslicarbazepine	2013-06-12	2014-07-08	2014-08-07	List with criteria/condition	2015-04-16	2014-08-15			1	2015-09-08	Positive
Ofatumumab	2011-01-21	2012-03-09	2012-08-13	Do not reimburse	2015-01-29	2014-04-14			1	2015-02-27	Negotiations not pursued
Teriflunomide	2012-11-29	2013-11-14	2013-11-15	Do not list at the submitted price	2014-06-18	2013-08-28			1	2014-09-26	Positive
Rufinamide	2010-07-06	2011-06-22	2011-10-20	List with clinical criteria and/or conditions	2012-03-15	2011-09-20			1		

Avelumab	2017-03-23	2017-12-18	2017-12-18	Reimburse with clinical criteria and/or conditions	2018-03-21	2020-09-18		1	2019-01-17	Positive
Belimumab	2010-07-15	2011-07-06	2011-08-24	Do not list	2012-04-25	2011-09-19		1	2014-01-31	Negotiations not pursued
brolocizumab	2019-03-27	2020-03-12	2020-05-15	Reimburse with clinical criteria and/or conditions	2020-05-21	2019-09-26		1	2021-08-31	Positive
Inotuzumab ozogamicin	2017-03-30	2018-03-15	2018-05-03	Reimburse with clinical criteria and/or conditions	2018-07-06	2017-11-13		1	2019-02-06	Positive
Bictegravir sodium, emtricitabine, tenofovir alafenamide hemifumarate	2017-07-26	2018-07-10	2018-08-08	Reimburse with clinical criteria and/or conditions	2018-10-25	2018-04-30		1	2019-06-14	Positive
Blinatumomab	2015-01-30	2015-12-22	2016-03-17	Reimburse with clinical criteria and/or conditions	2016-04-01	2015-08-24		1	2017-01-09	Positive
Bosutinib	2011-12-20	2014-03-14	2014-04-24	Reimburse with clinical criteria and/or conditions	2015-04-21	2014-05-30		1	2015-11-09	Positive
Fluticasone and vilatnerol	2012-07-20	2013-07-03	2013-11-29	List with criteria/condition	2014-08-18	2013-10-29		1	2015-02-03	Positive
Ticagrelor	2010-02-08	2011-05-30	2011-06-01	Do not list	2011-12-16	2011-06-01		1	2012-09-12	Positive
Cerliponase Alfa	2018-05-25	2018-12-19	2019-03-18	Reimburse with clinical criteria and/or conditions	2019-05-23	2018-07-31	1		2020-01-22	Positive
Brivaracetam	2015-03-30	2016-03-09	2016-05-02	Reimburse with clinical criteria and/or conditions	2017-01-25	2016-04-19		1	2018-10-22	Positive
Exenatide	2009-04-06	2011-01-13	2011-06-01	Do not list	2012-07-19	2011-08-23		1	2013-06-13	Negative
Nebivolol	2011-12-23	2012-12-21	2013-04-02	Do not list at the submitted price	2013-07-18	2013-02-04		1	2013-08-22	Negotiations not pursued
cabotegravir, rilpivirine	2019-04-29	2020-03-18	2020-09-21	Reimburse with clinical criteria and/or conditions	2020-07-22	2019-08-19			2021-09-07	Positive
caplacizumab	2019-07-22	2020-02-28	2020-09-04	Do not reimburse	2020-08-26	2019-09-13			2020-10-23	Negotiations not pursued

acalabrutinib	2018-03-15	2019-08-23	2019-10-02	Reimburse with clinical criteria and/or conditions	2020-11-17		1	2021-10-05	Positive
Vandetanib	2011-01-27	2012-01-12	2012-02-23	Reimburse with clinical criteria and/or conditions	2017-03-30	2016-08-15	1	2018-06-01	Positive
Eliglustat	2015-03-19	2017-04-21	2017-07-26	Reimburse with clinical criteria and/or conditions	2017-07-26	2017-01-20	1	2018-05-31	Positive
Reslizumab	2015-07-03	2016-07-20	2016-12-19	Reimburse with clinical criteria and/or conditions	2017-03-22	2016-08-04		2018-11-15	Negative
Linacotide	2012-12-14	2013-12-02	2014-04-29	Do not list	2015-09-23	2014-12-17	1	2015-11-02	Negotiations not pursued
Ranolazine	2020-05-27	2020-12-31	2021-05-03	Do not reimburse	2021-05-27	2020-08-17	1		Under consideration
Secukinumab	2013-12-17	2015-02-27	2015-09-25	List with criteria/condition	2015-10-28	2014-12-08	1	2016-06-08	Positive
Cobimetinib	2015-03-12	2016-02-22	2016-04-06	Reimburse with clinical criteria and/or conditions	2016-06-30	2015-12-11	1	2017-05-11	Positive
Isavuconazonium sulfate	2017-10-26	2018-12-19	2019-05-02	Reimburse with clinical criteria and/or conditions	2019-05-15	2018-11-02		2019-11-25	Positive
Burosumab	2018-05-16	2018-12-05	2019-01-28	Reimburse with clinical criteria and/or conditions	2020-05-27	2019-07-23		2021-09-10	Positive
Ramucirumab	2014-07-28	2015-07-16	2015-09-10	Reimburse with clinical criteria and/or conditions	2015-10-29	2015-04-15	1	2016-10-27	Positive
Daclatasvir	2014-05-16	2015-08-13	2015-09-08	List with clinical criteria and/or conditions	2015-09-21	2015-02-13	1	2017-02-17	Positive
Daratumumab	2015-09-14	2016-06-29	2016-07-12	Do not reimburse	2016-12-01	2016-04-21	1	2018-11-14	Positive
Glasdegib	2019-03-15	2020-04-28	2020-08-10	Do not reimburse	2021-01-08	2020-05-06		2021-02-23	Negotiations not pursued
Stiripentol	2010-10-08	2012-12-21	2013-05-01	List with criteria/condition	2014-10-16	2013-10-30	1	2015-05-11	Positive
Fidaxomicin	2011-11-02	2012-06-07	2012-06-21	Do not list at the submitted price	2012-12-19	2012-07-10	1	2013-11-13	Positive

Dupilumab	2016-12-16	2017-11-30	2018-02-06	Do not reimburse	2018-06-27	2017-10-27		1	2019-09-17	Positive
Azelastine and fluticasone	2013-12-04	2014-10-23	2015-03-31	Do not list	2015-06-17	2014-12-09		1	2015-07-24	Negotiations not pursued
Azilsartan	2011-03-28	2012-03-08	2012-11-08	Do not list at the submitted price	2013-10-17	2013-03-08		1	2013-11-12	Negotiations not pursued
Rilpivirine	2010-08-13	2011-07-21	2011-08-31	List	2012-02-15	2011-07-29		1		
Doxycycline	2010-12-02	2011-11-14	2012-11-29	Do not list	2013-03-27	2012-04-27				
Tesamorelin	2011-06-17	2014-04-29	2015-06-23	Do not reimburse	2016-08-24	2016-03-02		1	2016-10-14	Negotiations not pursued
Taliglucerase Alfa	2013-06-18	2014-05-29	2014-09-08	Do not list	2015-10-28	2014-08-15		1	2018-05-17	Positive
Apixaban	2010-10-05	2011-12-16	2012-02-01	List with clinical criteria and/or conditions	2012-06-14	2011-12-20		1	2013-10-10	Positive
Satralizumab	2019-11-18	2020-06-01	2020-08-26	Reimburse with clinical criteria and/or conditions	2021-04-21	2020-10-22				Active negotiation
Sacubitril, Valsartan	2015-03-06	2015-10-02	2015-11-13	List with clinical criteria and/or conditions	2016-03-18	2015-09-18	1		2017-03-06	Positive
Vedolizumab	2013-11-21	2015-01-29	2015-04-21	List with clinical criteria and/or conditions	2015-10-28	2015-02-20		1	2017-03-03	Positive
Sofosbuvir + Velpatasvir	2015-12-14	2016-07-11	2016-08-02	Reimburse with clinical criteria and/or conditions	2016-10-26	2016-04-22		1	2017-02-17	Positive
Vismodegib	2012-04-02	2013-07-12	2013-08-09	Reimburse with clinical criteria and/or conditions	2014-01-10	2013-06-14		1	2014-04-01	Positive
Apalutamide	2017-12-07	2018-07-03	2018-07-27	Reimburse with clinical criteria and/or conditions	2018-11-01	2018-04-16		1	2019-07-09	Positive
Pirfenidone	2012-03-02	2012-10-01	2013-01-08	Do not list	2013-04-18	2012-10-05		1	2014-08-15	Positive
Crisaborole	2017-06-23	2018-06-07	2018-08-29	Do not reimburse	2019-03-27	2018-05-25			2019-04-16	Negotiations not pursued
romosozumab	2016-08-18	2019-06-17	2019-08-12	Reimburse with clinical criteria and/or conditions	2021-11-11	2021-02-01		1		Under consideration for negotiation
Aflibercept	2011-08-17	2013-11-08	2013-12-23	List with criteria/condition	2014-10-20	2013-11-18		1	2015-03-27	Positive

Fampridine	2009-12-07	2012-02-10	2012-02-24	Do not list	2012-11-28	2012-04-16		1	2014-01-31	Negotiations not pursued
Benralizumab	2017-03-21	2018-02-22	2018-03-28	Reimburse with clinical criteria and/or conditions	2018-08-21	2018-02-23		1	2019-05-03	Positive
Deferiprone	2013-03-07	2015-02-13	2016-07-28	List with clinical criteria and/or conditions	2016-03-18	2015-09-24		1	2016-09-07	Positive
Ulipristal	2012-06-29	2013-06-24	2013-07-04	List with criteria/condition	2013-11-15	2013-04-17		1	2015-09-18	Positive
Icatibant	2013-03-05	2014-06-04	2014-07-14	List with clinical criteria and/or conditions	2014-12-19	2014-03-04		1	2015-08-28	Positive
Pralatrexate	2017-07-18	2018-10-26	2019-01-15	Reimburse with clinical criteria and/or conditions	2019-04-04	2018-06-01			2020-01-10	Positive
Dapagliflozin	2012-12-07	2014-12-12	2015-01-16	List with clinical criteria and/or conditions	2015-11-20	2015-04-30		1	2016-10-03	Positive
Perampanel	2012-02-29	2013-04-04	2013-06-19	List with criteria/condition	2013-10-17	2013-03-08		1	2019-07-02	Positive
Migalastat	2016-07-15	2017-09-05	2018-01-15	Reimburse with clinical criteria and/or conditions	2018-01-24	2017-06-09		1	2018-08-28	Positive
Simeprevir	2013-04-15	2013-11-18	2013-11-25	List with criteria/condition	2014-06-18	2013-08-22		1	2014-08-20	Positive
Obinutuzumab	2013-10-02	2014-11-25	2014-11-28	Reimburse	2015-01-27	2014-08-11	1		2015-05-15	Positive
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Hemifumarate	2015-01-19	2015-11-27	2016-02-03	List	2016-03-18	2015-09-24		1	2017-03-13	Positive
Fingolimod	2010-03-23	2011-03-09	2011-03-28	List with clinical criteria and/or conditions	2011-11-16	2011-05-10		1	2013-03-04	Positive
Afatinib	2012-09-12	2013-11-01	2014-01-17	Reimburse	2014-05-02	2013-06-07		1	2014-07-03	Positive
Eribulin	2010-12-31	2011-12-14	2012-03-19	Reimburse with clinical criteria and/or conditions	2012-08-02	2012-02-09		1	2013-07-02	Positive

Ledipasvir and sofosbuvir	2014-03-20	2014-10-15	2014-10-16	List with criteria/condition	2015-03-18	2014-09-15		1	2015-02-05	Positive
Emicizumab	2018-01-09	2018-08-02	2018-10-19	Reimburse with clinical criteria and/or conditions	2020-12-21	2020-06-30	1			
Ritonavir, paritaprevir, ombitasvir, dasabuvir	2014-05-14	2014-12-22	2015-01-06	List with clinical criteria and/or conditions	2015-06-18	2014-12-03		1	2015-06-16	Positive
Ponatinib	2013-05-23	2015-04-02	2015-08-21	Reimburse with clinical criteria and/or conditions	2015-10-01	2015-03-13		1	2016-07-04	Positive
Enasidenib mesylate	2018-06-15	2019-02-06	2019-02-27	Do not reimburse	2019-10-31	2019-04-05				Under consideration for negotiation
Ibrutinib	2014-04-17	2014-11-17	2014-11-19	Reimburse with clinical criteria and/or conditions	2015-03-05	2014-08-15	1		2015-06-02	Positive
Durvalumab	2017-02-16	2017-11-03	2017-11-20	Reimburse with clinical criteria and/or conditions	2019-05-03	2018-09-21		1	2019-08-26	Positive
Telaprevir	2011-01-14	2011-08-16	2011-10-03	List with clinical criteria and/or conditions	2012-02-15	2011-08-23		1		
Mecasermin	2020-01-09	2020-12-17	2021-03-01	Reimburse with clinical criteria and/or conditions	2022-01-21	2021-06-14				Under consideration for negotiation
Axitinib	2011-06-28	2012-07-12	2012-08-17	Reimburse	2013-03-07	2012-08-16		1	2013-11-22	Positive
Fedratinib	2019-07-19	2020-07-27	2021-05-20	Reimburse with clinical criteria and/or conditions	2021-06-21	2020-11-05				Active negotiation
Romidepsin	2011-12-22	2013-10-16	2014-02-05	Reimburse with clinical criteria and/or conditions	2015-05-19	2014-12-01		1	2015-09-16	Positive
Ruxolitinib	2011-11-29	2012-06-19	2012-07-19	Reimburse with clinical criteria and/or conditions	2013-01-14	2012-06-25		1	2013-09-03	Positive
Empagliflozin	2013-04-17	2015-07-23	2015-08-11	List with clinical criteria and/or conditions	2015-10-15	2015-04-23		1	2016-04-13	Positive

Ocriplasmin	2012-12-24	2013-08-13	2013-11-20	List with criteria/condition	2013-12-20	2013-06-06	1	2014-10-10	Positive	
Efinaconazole	2012-10-19	2013-10-02	2014-07-21	Do not reimburse	2019-05-23	2018-08-02		1	2019-06-19	Negotiations not pursued
Lomitapide	2012-11-21	2014-02-04	2014-05-06	Do not list	2015-04-17	2014-07-08		1	2015-05-26	Negotiations not pursued
Trastuzumab emtansine	2013-02-08	2013-09-11	2013-10-09	Reimburse with clinical criteria and/or conditions	2014-01-10	2013-03-15		1	2014-03-31	Positive
Ivacaftor	2012-04-30	2012-11-26	2012-11-27	List with criteria/condition	2013-03-22	2012-09-27	1		2014-06-16	Positive
Sebelipase Alfa	2017-03-23	2017-12-15	2018-04-05	Reimburse with clinical criteria and/or conditions	2018-09-26	2017-11-02	1		2020-10-21	Positive
Sarilumab	2016-01-29	2017-01-12	2017-03-29	Reimburse with clinical criteria and/or conditions	2017-04-18	2016-10-12		1	2019-02-26	Positive
Pembrolizumab	2014-06-23	2015-05-19	2015-06-01	Reimburse with clinical criteria and/or conditions	2015-11-16	2015-04-16		1	2016-02-10	Positive
Ribociclib	2017-03-17	2018-03-02	2018-04-27	Reimburse with clinical criteria and/or conditions	2018-04-18	2017-10-17		1	2019-04-26	Positive
Carfilzomib	2015-05-19	2016-01-15	2016-02-11	Reimburse with clinical criteria and/or conditions	2017-03-30	2016-09-09		1	2017-12-08	Positive
Ivabradine	2013-08-23	2016-12-23	2017-03-17	Reimburse with clinical criteria and/or conditions	2017-05-24	2016-11-08		1	2018-08-22	Positive
Olaratumab	2017-03-06	2017-11-23	2017-12-22	Reimburse with clinical criteria and/or conditions	2018-04-18	2017-10-26		1	2019-01-31	Negative
Lurasidone	2011-06-30	2012-06-13	2012-09-06	List with criteria/condition	2013-12-20	2012-07-03		1		
Lenvatinib	2015-01-08	2015-12-22	2016-03-31	Reimburse with clinical criteria and/or conditions	2016-09-20	2016-04-18		1	2017-06-16	Positive
cemiplimab	2018-07-27	2019-04-10	2019-05-24	Reimburse with clinical criteria and/or conditions	2020-01-22	2019-07-09		1	2020-11-04	Positive

Edoxaban	2015-09-03	2016-11-04	2017-04-25	Reimburse with clinical criteria and/or conditions	2017-03-21	2016-09-09	1	2019-02-05	Positive
Colesevelam	2009-10-09	2011-09-22	2012-02-06	Do not list at the submitted price	2012-12-19	2012-04-27	1	2014-04-16	Positive
sodium zirconium cyclosilicate	2018-08-15	2019-07-25	2019-10-17	Do not reimburse	2020-03-25	2019-05-17		2020-04-16	Negotiations not pursued
Trifluridine, tipiracil	2017-05-30	2018-01-25	2018-03-22	Do not reimburse	2018-07-06	2017-11-06	1	2019-08-08	Positive
Lorlatinib	2018-06-26	2019-02-22	2019-04-22	Do not reimburse	2020-01-30	2019-06-11	1	2020-04-21	Negotiations not pursued
Lutetium (177Lu) oxodotreotide	2018-06-18	2019-01-09	marketed - no	Reimburse with clinical criteria and/or conditions	2019-08-01	2018-07-30			
Voretigene neparvovec	2019-10-31	2020-10-13		Reimburse with clinical criteria and/or conditions	2020-11-12	2020-04-23			
Olaparib	2015-03-16	2016-04-29	2016-05-16	Do not reimburse	2016-09-29	2016-04-01	1	2018-05-15	Positive
Trientine	2019-08-07	2020-09-14	2020-11-10	Reimburse with clinical criteria and/or conditions	2021-11-11	2021-04-19	1		Active negotiation
Pibrentasvir, glecaprevir	2017-01-24	2017-08-16	2017-09-13	Reimburse with clinical criteria and/or conditions	2018-01-23	2017-06-09	1	2018-12-19	Positive
siponimod	2018-12-21	2020-02-20	2020-04-24	Reimburse with clinical criteria and/or conditions	2020-07-21	2019-09-26	1	2021-10-22	Positive
Trametinib	2012-08-03	2013-07-18	2013-08-28	Reimburse with clinical criteria and/or conditions	2013-10-22	2013-05-06	1	2014-06-25	Positive
Propiverine	2015-10-23	2017-01-05	2017-05-08	Reimburse with clinical criteria and/or conditions	2017-04-19	2016-10-14	1	2018-02-12	Negative
Mifepristone and Misoprostol	2012-11-14	2015-07-29	2017-01-10	Reimburse	2017-04-18	2016-10-07	1	2017-07-05	Positive
Iron isomaltoside 1000	2016-04-28	2018-06-22	2018-10-17	Reimburse with clinical criteria and/or conditions	2020-03-25	2019-06-26		2021-02-02	Positive
Plerixafor	2010-12-21	2011-12-08	2012-03-26	Do not list	2012-09-26	2012-01-24	1	2014-01-06	Positive
gemtuzumab oxogamicin	2018-12-17	2019-11-28	2020-03-11	Reimburse	2020-04-02	2019-08-09	1	2020-08-12	Positive

Mirabegron	2012-03-19	2013-03-06	2013-03-28	List with criteria/condition	2014-11-12	2013-11-27		1	2015-04-08	Positive
Galsulfase	2012-09-28	2013-09-16	2014-01-01	List with clinical criteria and/or conditions	2016-02-19	2015-08-20	1		2017-01-31	Negoations not pursued
neratinib maleate	2018-07-19	2019-07-16	2019-12-20	Do not reimburse	2019-12-05	2019-04-18			2020-02-04	Negotiations not pursued
Alogliptin	2012-08-29	2013-11-27	2014-04-30	Do not list	2015-01-15	2014-01-30		1	2015-01-28	Negotiations not pursued
Rotigotine	2011-03-30	2013-03-21	2013-12-19	Do not list	2014-05-28	2013-07-31	1		2017-06-23	Positive
Ixazomib	2015-12-14	2016-08-04	2016-09-21	Do not reimburse	2017-06-29	2016-12-16		1	2017-08-18	Negotiations not pursued
darolutamide	2019-03-27	2020-02-20	2020-03-24	Reimburse with clinical criteria and/or conditions	2020-04-22	2019-08-27			2021-02-18	Positive
Mepolizumab	2014-11-19	2015-12-03	2016-03-14	Reimburse with clinical criteria and/or conditions	2016-06-16			1	2017-11-24	Positive
Obeticholic acid	2016-09-16	2017-05-24	2017-05-26	Reimburse with clinical criteria and/or conditions	2017-07-25	2016-12-22	1		2018-06-27	Positive
Ocrelizumab	2016-09-16	2017-08-14	2017-09-21	Reimburse with clinical criteria and/or conditions	2017-11-21	2017-05-16		1	2019-02-13	Positive
Sonidegib	2019-07-04	2020-06-12	2020-12-23	Do not reimburse	2021-04-29	2020-06-19		1	2021-06-04	Negotiations not pursued
Nintedanib	2014-07-09	2015-06-25	2015-06-29	List with clinical criteria and/or conditions	2015-10-15	2015-04-23		1	2016-08-29	Positive
Baricitinib	2016-03-29	2018-08-17	2018-09-27	Reimburse with clinical criteria and/or conditions	2019-08-02	2018-12-20		1	2021-05-10	Positive
Indacaterol	2010-12-22	2011-12-06	2012-03-05	List in a similar manner	2012-08-16	2012-02-29		1	2013-04-12	Positive
patisiran sodium	2018-11-14	2019-06-07	2019-07-25	Reimburse with clinical criteria and/or conditions	2019-07-25	2019-01-25	1		2020-11-30	Positive
safinamide mesylate	2017-11-08	2019-01-10	2019-07-08	Do not reimburse	2020-03-25	2019-05-29		1		Under consideration for negotiation

Nivolumab	2014-12-19	2015-09-25	2015-10-23	Reimburse with clinical criteria and/or conditions	2016-04-01	2015-08-13	1	2017-01-20	Positive	
Macitentan	2012-12-24	2013-11-06	2014-01-15	List with clinical criteria and/or conditions	2015-01-28	2013-12-18		1	2020-12-23	Positive
Nitisinone	2016-03-30	2016-12-13	2017-02-17	Reimburse with clinical criteria and/or conditions	2018-02-21	2017-08-29	1		2018-11-28	Positive
Ivacaftor, Lumacaftor	2015-01-30	2016-01-26	2016-01-27	Do not reimburse	2018-09-26	2018-02-22		1	2021-06-03	Positive
Apremilast	2013-11-08	2014-11-12	2014-11-27	Do not list	2015-07-22	2014-10-08		1	2017-09-08	Negative
Ozenoxacin	2016-04-01	2017-05-01	2018-01-04	Do not reimburse	2018-10-24	2018-01-25		1	2018-11-30	Negotiations not pursued
Semaglutide	2017-01-19	2018-01-04	2018-02-22	Reimburse with clinical criteria and/or conditions	2019-05-15	2018-11-23		1	2019-07-26	Positive
Pertuzumab	2012-08-31	2013-04-12	2013-05-08	Reimburse with clinical criteria and/or conditions	2013-08-01	2012-11-02	1		2015-07-29	Negotiations not pursued
Sodium phenylbutyrate	2014-06-13	2015-01-26	2015-01-27	List	2016-04-15	2015-10-20		1	2017-11-20	Positive
Ingenol	2012-02-09	2013-01-30	2013-03-21	Do not list	2014-01-22	2013-05-09		1	2014-12-02	Negotiations not pursued
Doravirine	2017-11-17	2018-10-12	2018-11-14	Reimburse with clinical criteria and/or conditions	2019-05-14	2018-11-16		1	2019-10-15	Positive
alpelisib	2019-04-17	2020-03-11	2020-06-29	Do not reimburse	2022-01-26	2021-04-21				Under consideration for negotiation
Peginterferon Beta-1A	2013-07-31	2015-08-10	2015-09-29	List with criteria/condition	2015-12-17	2015-06-26			2017-02-14	Positive
Polatuzumab vedotinxx	2019-10-07	2020-07-09	2020-11-25	Reimburse with clinical criteria and/or conditions	2021-04-21	2020-09-29		1	2021-12-01	Positive
Pomalidomide	2013-06-20	2014-01-20	2014-02-24	Reimburse with clinical criteria and/or conditions	2014-07-31	2014-01-13	1		2015-01-23	Positive

Alirocumab	2015-03-20	2016-04-11	2016-08-13	Reimburse with clinical criteria and/or conditions	2016-07-20	2016-01-12		1	2018-08-02	Positive
Letemovir	2017-04-10	2017-11-01	2017-12-20	Reimburse with clinical criteria and/or conditions	2018-06-20	2017-12-07		1	2019-12-18	Positive
Cysteamine	2016-01-21	2017-06-13	2017-10-17	Reimburse with clinical criteria and/or conditions	2018-01-24	2017-08-08	1		2018-07-20	Positive
Edaravone	2018-03-09	2018-10-03	2019-10-29	Reimburse with clinical criteria and/or conditions	2019-03-27	2018-07-05			2020-04-15	Positive
Silodosin	2009-12-21	2011-01-11	2011-10-26	Do not list	2012-04-19	2011-10-25		1		
Glycerol Phenylbutyrate	2014-04-25	2016-03-16	2016-11-03	Reimburse with clinical criteria and/or conditions	2017-03-21	2016-08-30			2017-12-12	Positive
Luspatercept	2020-03-05	2020-09-25	2020-11-23	Reimburse with clinical criteria and/or conditions	2021-06-08	2020-11-26				Under consideration for negotiation
Evolocumab	2014-09-25	2015-09-10	2015-09-28	List with clinical criteria and/or conditions	2016-02-19	2015-06-30		1	2017-10-23	Positive
Prucalopride	2010-12-17	2011-12-07	2012-01-12	Do not list	2012-07-19	2012-01-30		1		
Teduglutide	2014-12-01	2015-09-04	2015-10-28	Reimburse with clinical criteria and/or conditions	2016-07-27	2015-11-26		1	2018-08-07	Positive
Eltrombopag	2008-12-08	2011-01-12	2011-04-04	Do not list	2011-10-24	2011-04-26		1	2015-05-28	Negotiations not pursued
Brexipiprazole	2016-02-26	2017-02-16	2017-04-19	Reimburse with clinical criteria and/or conditions	2017-11-22	2017-02-03		1	2018-12-14	Positive
upadacitinib	2019-01-16	2019-12-23	2020-01-16	Reimburse with clinical criteria and/or conditions	2020-02-04	2019-07-04		1		Active negotiation
Ivermectin	2014-05-06	2015-04-22	2015-05-25	List with criteria/condition	2015-11-19	2015-04-30		1	2016-08-26	Negative
entrectinib	2019-05-08	2020-02-10	2020-03-10	Reimburse with clinical criteria and/or conditions	2021-01-27	2020-01-08			2021-07-06	Positive

Amifampridine	2019-12-20	2020-08-10	2020-09-24	Reimburse with clinical criteria and/or conditions	2021-04-20	2020-10-05				Active negotiation
Midostaurin	2016-12-09	2017-07-21		Reimburse	2017-12-19	2017-06-12	1			
Tolvaptan	2010-08-18	2011-07-25	2011-09-22	Do not list	2013-02-13	2012-07-03		1	2014-01-31	Negotiations not pursued
Asenapine	2009-11-12	2011-10-07	2011-12-19	List with clinical criteria and/or conditions	2012-06-14	2011-12-12		1		
Isatuximab	2019-06-28	2020-04-29	2020-07-03	Reimburse with clinical criteria and/or conditions	2021-04-01	2020-08-17		1		Under consideration for negotiation
Pasireotide	2011-02-08	2013-09-23	2013-11-26	Do not list	2015-02-24	2014-02-27	1		2015-04-30	Negotiations not pursued
Brodalumab	2016-05-24	2018-03-06	2018-07-05	Reimburse with clinical criteria and/or conditions	2018-06-20				2018-12-14	Positive
risankizumab	2018-05-07	2019-04-17	2019-05-13	Reimburse with clinical criteria and/or conditions	2019-05-28	2018-10-22		1	2019-11-28	Positive
Sofosbuvir	2013-05-21	2013-12-13	2014-01-06	List with criteria/condition	2014-08-18	2013-10-01	1		2015-02-05	Positive
Nusinersen	2016-11-10	2017-06-29	2017-08-29	Reimburse with clinical criteria and/or conditions	2017-12-22	2017-06-28			2018-09-26	Positive
Ertugliflozin	2017-04-13	2018-05-09	2018-05-28	Do not reimburse	2019-01-23	2018-04-30		1	2020-03-31	Negative
Regorafenib	2012-08-15	2013-03-11	2013-04-02	Do not reimburse	2013-11-15	2013-03-22		1	2014-08-11	Positive
Asfotase Alfa	2014-11-14	2015-08-14	2015-10-20	List with criteria/condition	2016-03-23	2015-08-21	1		2018-01-09	Positive
Elvitgravir, Emtricitabine, Tenofovir, Cobicistat	2011-12-19	2012-11-26	2012-12-20	List with criteria/condition	2013-05-15	2012-11-30		1	2013-07-11	Positive
Asunaprevir	2014-05-16	2016-03-09	2016-04-22	Reimburse with clinical criteria and/or conditions	2016-07-20	13-Feb-15		1	2017-02-17	Positive
Siltuximab	2014-04-28	2014-12-03	2015-03-03	Reimburse with clinical criteria and/or conditions	2015-06-22	2015-01-30		1	2013-08-14	Positive

Dabrafenib	2012-07-31	2013-07-16	2013-08-28	Reimburse with clinical criteria and/or conditions	2013-12-05	2013-03-18	1	2014-06-25	Positive
Osimertinib	2015-10-01	2016-07-05	2016-07-19	Reimburse with clinical criteria and/or conditions	2017-05-04	2016-04-01	1	2018-07-30	Positive
Lanadelumab	2018-02-22	2018-09-19	2018-10-31	Reimburse with clinical criteria and/or conditions	2019-11-19	2019-05-29	1	2020-10-30	Positive
Ixekizumab	2015-06-05	2016-05-25	2016-08-11	Reimburse with clinical criteria and/or conditions	2016-10-25	2016-03-23	1	2017-12-29	Positive
Atezolizumab	2016-07-18	2017-04-12	2017-05-02	Reimburse with clinical criteria and/or conditions	2018-06-20	2017-12-15	1	2018-11-29	Positive
Dimethyl fumarate	2012-04-16	2013-04-03	2013-04-12	List with criteria/condition	2013-09-25	2013-02-04	1	2014-04-10	Positive
Inotersen sodium	2018-03-17	2018-10-03	2019-01-07	Reimburse with clinical criteria and/or conditions	2019-12-18	2019-02-22		2020-04-30	Positive
Dolutegravir	2012-12-17	2013-10-31	2013-11-08	List	2014-08-18	2013-10-18	1	2015-04-08	Positive
Fesoterodine	2011-03-01	2012-02-09	2012-04-19	List in a similar manner	2012-10-18	2012-04-27	1		
Linagliptin	2010-08-17	2011-07-28	2011-09-13	List with clinical criteria and/or conditions	2012-02-15	2011-08-23	1		
Bendamustine	2011-09-08	2012-08-24	2012-09-12	Reimburse	2012-11-29	2012-04-24	1	2013-04-25	Positive
Guselkumab	2016-12-25	2017-11-10	2017-11-27	Reimburse with clinical criteria and/or conditions	2018-02-21	2017-08-25	1	2019-06-21	Negative
Flextouch (insulin degludec)	2016-09-13	2017-08-25	2017-09-15	Reimburse with clinical criteria and/or conditions	2017-11-20	2017-05-31	1	2018-07-26	Positive
Dulaglutide	2014-02-10	2015-11-10	2016-01-08	Reimburse with clinical criteria and/or conditions	2016-06-16	2015-12-22	1	2019-09-27	Negative
Acidinium	2012-07-31	2013-07-29	2013-09-13	List with criteria/condition	2014-04-21	2013-08-21	1	2014-07-16	Positive

Tucatinib	2020-01-20	2020-06-05	2020-10-08	Reimburse with clinical criteria and/or conditions	2021-11-17	2021-03-26			Under consideration for negotiation
Dinutuximab	2017-12-14	2018-11-28	2019-05-01	Reimburse with clinical criteria and/or conditions	2019-03-26	2018-10-01		2019-08-30	Positive
Selexipag	2015-02-13	2016-01-20	2016-04-21	Reimburse with clinical criteria and/or conditions	2016-10-28	2016-03-31	1	2017-12-12	Positive
icosapent ethyl	2019-04-29	2019-12-30	2020-02-07	Reimburse with clinical criteria and/or conditions	2020-07-16	2019-06-17	1		Active negotiation
Sucroferric oxyhydroxide	2016-12-22	2018-01-05	2019-11-20	Reimburse with clinical criteria and/or conditions	2019-01-02	2018-06-12		2019-09-17	Positive
Patiromer sorbitex calcium	2017-10-20	2018-10-03	2020-03-09	Reimburse with clinical criteria and/or conditions	2021-06-08	2020-10-30		2022-02-18	Negative
Abemaciclib+A3:M 331	2018-04-16	2019-04-05	2019-07-03	Reimburse with clinical criteria and/or conditions	2019-07-05		1	2020-04-09	Negative
Eluxadoline	2015-12-11	2017-01-26	2017-04-24	Do not reimburse	2018-08-24	2018-02-23	1	2018-11-07	Negotiations not pursued
Boceprevir	2010-12-22	2011-07-29	2011-08-02	List with clinical criteria and/or conditions	2011-10-24	2011-05-03	1		
Elosulfase Alfa Dienogest	2013-11-26 2009-08-21	2014-07-02 2011-10-12	2014-08-27 2011-10-25	Do not list List with clinical criteria and/or conditions	2015-03-25 2012-04-19	2014-08-05 2011-10-18		2018-11-29	Positive
larotrectinib	2018-09-18	2019-07-10	2020-11-13	Do not reimburse	2019-10-31	2019-02-25	1	2019-12-30	Negotiations not pursued
Dacomitinib monohydrate	2018-03-16	2019-02-26	2019-04-22	Reimburse with clinical criteria and/or conditions	2019-05-31	2018-09-19		2020-02-11	Negative
von Willebrand factor (recombinant)	2018-01-26	2019-01-10		Reimburse with clinical criteria and/or conditions	2021-03-17	2020-04-29			

Sofosbuvir, velpatasvir, voxilaprevir	2017-01-27	2017-08-16	2017-09-18	Reimburse with clinical criteria and/or conditions	2018-01-23	2017-07-28	1	2018-02-14	Positive
tafamidis meglumine	2019-06-03	2020-01-20	2020-04-07	Reimburse with clinical criteria and/or conditions	2020-02-19	2019-07-04	1	2021-02-04	Positive
Latanoprostene Bunod	2018-01-24	2018-12-27	2019-05-17	Reimburse with clinical criteria and/or conditions	2019-07-24	2018-11-23	1	2019-11-20	Positive
Crizotinib	2011-06-08	2012-04-12	2012-05-10	Do not reimburse	2012-10-04	2012-03-26	1	2013-08-08	Positive
Tofacitinib	2012-04-03	2014-04-17	2014-06-03	List with criteria/condition	2015-04-17	2014-05-05	1	2016-04-26	Positive
Telotristat etiprate	2017-11-01	2018-10-10	2018-12-07	Do not reimburse	2019-06-26	2018-09-27	1	2019-07-12	Negotiations not pursued
Collagenase clostridium histolyticum	2011-06-07	2012-07-05	2012-11-14	List with criteria/condition	2013-03-27	2012-08-30	1	2014-03-18	Negotiations not pursued
gilteritinib fumarate	2019-05-22	2019-12-23	2020-02-03	Reimburse with clinical criteria and/or conditions	2020-05-20	2019-10-28	1	2021-03-15	Positive
Enzalutamide	2012-10-26	2013-05-29	2013-06-07	Reimburse with clinical criteria and/or conditions	2013-07-23	2013-03-04	1	2013-09-23	Positive
Ipilimumab	2010-10-13	2012-02-01	2012-03-08	Reimburse with clinical criteria and/or conditions	2012-04-18	2011-12-01	1	2012-08-28	Positive
Aflibercept	2012-05-09	2014-02-12	2014-05-08	Do not reimburse	2014-09-05	2013-11-26	1	2014-09-25	Negotiations not pursued
Rifaximin	2013-01-14	2013-08-13	2013-11-07	List with criteria/condition	2015-04-16	2014-08-05	1	2016-03-02	Positive
niraparib	2018-06-04	2019-06-27	2020-01-09	Reimburse with clinical criteria and/or conditions	2020-09-03	2020-02-07	1	2021-08-11	Positive
Vemurafenib	2011-07-18	2012-02-15	2012-03-05	Reimburse with clinical criteria and/or conditions	2012-06-01	2011-12-06	1		
Elbasvir, Grazoprevir	2015-06-30	2016-01-19	2016-01-25	Reimburse with clinical criteria and/or conditions	2016-05-19	2015-10-27	1	2017-02-17	Positive
Ozanimod	2019-10-25	2020-10-02	2020-11-12	Do not reimburse	2021-06-23	2020-08-25		2021-07-29	Negotiations not pursued

Daclizumab beta	2015-12-21	2016-12-08	2017-03-30	List with clinical criteria and/or conditions	2017-06-20	2016-12-20		1	2018-03-29	Negotiations not pursued
Onasemnogene abeparovvec	2020-05-21	2020-12-15	2021-02-04	Reimburse with clinical criteria and/or conditions	2021-03-24	2020-06-25			2021-10-08	Positive
Idelalisib	2014-02-28	2015-03-27	2015-04-21	Reimburse with clinical criteria and/or conditions	2015-08-18	2015-04-07		1	2016-06-03	Positive
Ceritinib	2014-06-16	2015-03-27	2015-04-29	Do not reimburse	2015-12-03	2015-06-05		1	2018-03-20	Positive
Abiraterone	2010-12-23	2011-07-27	2011-07-28	Reimburse with clinical criteria and/or conditions	2013-10-22			1	2014-01-23	Positive
Boceprevir, perinterferon alfa-2b, ribavirin	2011-01-05	2011-08-10	2011-08-16					1		
Cabazitaxel	2010-07-02	2011-06-16	2011-08-23					1		
Ferumoxytol	2009-12-18	2011-12-08	2012-05-01							
Catridecacog	2011-12-20	2012-07-19	2013-01-30					1		
Meningococcal polysaccharide conjugate vaccine	2012-03-21	2013-03-05	2013-08-22					1		
Diffuprednate	2012-11-20	2013-11-04	2014-02-19							
Multicomponent meningococcal B vaccine	2011-05-26	2013-12-06	2014-02-26					1		
Canagliflozin	2012-07-27	2014-05-23	2014-06-03	Withdrawn		2013-05-05				1
Vortioxetine	2012-09-28	2014-10-22	2014-10-28	Withdrawn		2014-10-31				1
Human papillomavirus 9 valent vaccine, recombinant	2014-02-13	2015-02-05	2015-03-18					1		
Naloxegol	2013-08-30	2015-06-02	2015-08-27							1
Carglumic Acid	2014-01-14	2015-04-10	2015-09-08					1		
Bromfenac	2014-04-04	2015-03-26	2015-09-25							
Levomilnacipran	2013-08-13	2015-05-08	2015-11-19							1
Recombinant human coagulation Factor IX, FC fusion protein	2013-03-28	2014-03-20	2015-12-11							1

Simoctocog alfa	2013-11-01	2014-10-23	2015-12-22				1
Ceftolozane Sulfate and Tazobactam Sodium	2014-09-15	2015-09-30	2016-01-12				1
Antihemophilic factor, FC fusion protein	2013-07-30	2014-08-22	2016-01-15				
Sugammadex	2014-12-23	2016-02-05	2016-02-19			1	
Palbociclib	2015-02-12	2016-03-16	2016-04-20	Withdrawn	2015-11-11		1
Idarucizumab	2015-03-04	2016-04-29	2016-05-24	Withdrawn			1
Venetoclax	2015-12-21	2016-09-30	2016-10-31	Withdrawn	2016-07-08		1
Polidocanol	2014-08-20	2015-08-04	2016-11-30				
Antihemophilic Factor (Recombinant) Porcine Sequence	2014-08-15	2015-10-14	2016-11-30				
Bilastine	2015-05-11	2016-04-21	2016-12-02				1
Conjugated estrogens and bazedoxifene acetate	2012-12-04	2014-10-23	2016-12-20				1
Rupatadine	2015-08-04	2016-07-20	2017-01-16				
Bepotastine	2015-08-19	2016-07-27	2017-03-23				1
Defibrotide	2016-12-09	2017-07-10	2017-09-06				1
Gadoterate Meglumine	2015-07-31	2016-11-25	2017-09-22				
Varicella-zoster virus glycoprotein E	2016-11-17	2017-10-13	2018-01-02			1	
Vernakalant	2016-01-04	2017-03-13	2018-01-23				1
Vilazodone	2014-07-29	2015-07-16	2018-01-31	CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer			

Neisseria meningitidis GRP B recombinant lipoprotein 2086 subfamily A, neisseria meningitidis GRP B recbominant 2086 subfamily B	2016-05-31	2017-10-05	2018-01-31			1
Lifitegrast	2016-10-28	2017-12-22	2018-02-12			
Antihemophilic Factor (Recombinant), PEGylated	2015-12-02	2016-11-17	2018-03-06			
Turoctocog alfa	2013-12-16	2014-12-08	2018-03-23			1
Coagulation factor IX (recombinant) pegylated	2016-12-12	2017-11-29	2018-03-23			1
Follitropin delta	2015-12-09	2018-03-22	2018-05-23			1
Tezacaftor, Ivacaftor	2017-11-17	2018-06-27	2018-06-28	CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer		1
Cabozantinib	2017-06-06	2018-09-14	2018-10-10	Withdrawn	2017-10-06	1
Elagolix sodium	2017-09-22	2018-10-05	2018-10-30	CADTH is unable to recommend reimbursement as a submission was not filed by the		1
Flibanserin	2015-11-18	2018-02-27	2018-11-13			
Panhematin	2017-12-20	2018-07-13	2018-12-05			
Suvorexant	2016-07-05	2018-11-29	2019-04-18			1
Tisagenlecleucel	2018-02-09	2018-09-05	2019-05-24			1
Albutrepenonacog Alfa	2015-02-09	2016-01-26	2019-07-04			

galcanezumab	2018-08-21	2019-07-30	2019-10-07	CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer			1
Axicabtagene ciloleucel	2018-07-23	2019-02-13	2019-11-27				1
trifarotene	2018-12-14	2019-11-25	2019-11-28				1
erdafitinib	2019-02-08	2019-10-25	2019-12-09				
Antihemophilic factor (recombinant, B-domain deleted, PEGylated)	2017-11-03	2018-10-18	2020-04-08				
tibolone	2017-06-01	2019-05-10	2020-07-29				1
Etomidate	2019-08-30	2020-07-15	2020-09-14				
cabotegravir sodium	2019-04-29	2020-03-18	2020-09-21				
Remdesivir	2020-06-19	2020-07-27	2020-10-16				
Amifampridine	2019-11-06	2020-07-31	2020-10-23	Active		2021-11-15	
Lemborexant	2019-09-03	2020-11-04	2020-11-06	Pending			
Cedazuridine, Decitabine	2019-12-31	2020-07-07	2020-11-11	Active		2020-10-09	
Tenapanor	2019-02-26	2020-04-15	2020-11-23				
Givosiran	2020-03-19	2020-10-09	2020-12-01	Reimburse with clinical criteria and/or conditions		2021-02-23	1
Ripretinib	2019-12-23	2020-06-19	2020-12-10	Active			
Fostamatinib	2019-09-30	2020-11-19	2020-12-10	Active		2021-07-22	
Decitabine	2017-12-28	2019-01-21	2021-03-24	CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer			
Dalbavancin	2017-12-21	2018-09-04	2021-05-28				1
ravulizumab	2018-09-13	2019-08-28	2021-09-09	Withdrawn		2019-07-04	
plecanatide	2018-09-20	2019-10-10	2022-01-12				
Rubidium chloride	2010-05-17	2011-09-20	marketed - no date				

Radium-223 dichloride	2012-12-21	2013-12-12	marketed - no date		1
Florbetaben 18F Ioflupane	2016-02-26	2017-02-22	marketed - no date		
oxodotreotide	2016-12-22	2017-12-07	marketed - no date		
gallium (68ga) chloride	2018-07-20	2019-07-03	marketed - no date		1
	2018-12-05	2019-11-13	marketed - no date		
Albiglutide	2013-05-24	2015-07-15	NOC cancelled pre-market		
Lubiprostone	2014-10-31	2015-10-14	NOC cancelled pre-market		
Necitumumab	2016-03-29	2017-03-16	NOC cancelled pre-market		
Ezogabine	2011-10-31	2012-10-08	not in Drug Product Database		
Botulinum antitoxin serotypes A, B,C, D, E, F and G	2015-12-22	2016-12-08	restricted access		
Anthrax immune globuline	2016-11-24	2017-11-06	restricted access		
Anthrax antigen filtrate	2017-12-29	2018-12-13	restricted access		
Clevidipine	2008-10-07	2011-04-15			
Remestemcel-L	2011-09-15	2012-05-17			
Haemagglutinin-Strain A	2007-07-05	2013-02-13			
Olodaterol	2012-06-28	2013-06-11			
Tafluprost	2013-06-10	2014-05-26			
Tedizolid	2014-04-01	2015-03-17	Withdrawn	2015-01-16	1
Finaxofloxacin	2014-06-05	2016-03-11			
Vorapaxar	2014-10-31	2016-05-13			
Elotuzumab	2015-10-01	2016-06-21			1
Lonococog Alfa	2015-12-23	2016-12-12			
Peramivir	2016-01-25	2017-01-05			
Calcifediol	2017-05-09	2018-07-10			
Cenegermi	2018-07-16	2019-02-08	Active	2021-10-29	1
antihemophilic factor viii pegylated decitabine	2018-07-23	2019-07-04			
	2018-06-29	2019-07-11			

talazoparib	2018-09-28	2019-09-06	CADTH is unable to recommend reimbursement as a submission was not filed		
prasterone	2016-10-05	2019-11-01	Active	2021-10-01	1
baloxavir marboxil	2019-04-30	2020-02-19	CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer		
Lefamulin	2019-11-07	2020-07-10			
Obiltoxaximab	2019-08-16	2020-07-30			
Gallium (68ga) chloride	2019-05-15	2020-08-19			